Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines the interactive effects of ketamine and nicotine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia

NCT00407277

Smoking Nicotine Dependence Schizophrenia +3 more

COMPLETED NA

The Effects of Nicotine on Cognition in Schizophrenia

NCT00383747

Schizophrenia

COMPLETED PHASE4

Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCT02675530

Schizophrenia

COMPLETED PHASE1

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085

Nicotine Dependence Schizophrenia

COMPLETED

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524

Tobacco Use Disorder Schizophrenia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine and Nicotine

* 0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.
* 13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)

Group Type ACTIVE_COMPARATOR

Ketamine and Nicotine

Intervention Type DRUG

0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.

13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)

Placebo Comparator

-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes

Ketamine and Placebo

Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes

Group Type ACTIVE_COMPARATOR

Ketamine

Intervention Type DRUG

Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

Nicotine and Placebo

Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

Group Type ACTIVE_COMPARATOR

Nicotine

Intervention Type DRUG

Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine

Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

Intervention Type DRUG

Nicotine

Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

Intervention Type DRUG

Placebo

Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes

Intervention Type DRUG

Ketamine and Nicotine

0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.

13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)

Intervention Type DRUG